| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURONEURO.2009.04.011 |
| P698 | PubMed publication ID | 19457646 |
| P50 | author | Claus Graff | Q40232530 |
| P2093 | author name string | Egon Toft | |
| Johannes J Struijk | |||
| Jimmi Nielsen | |||
| Jonathan M Meyer | |||
| Jens Kristoffersen | |||
| Mads P Andersen | |||
| Thomas Hardahl | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | electrocardiography | Q79785 |
| P304 | page(s) | 702-707 | |
| P577 | publication date | 2009-05-19 | |
| P1433 | published in | European Neuropsychopharmacology | Q15286536 |
| P1476 | title | Sertindole causes distinct electrocardiographic T-wave morphology changes | |
| P478 | volume | 19 |
| Q38153098 | Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram |
| Q33160123 | Assessing QT interval prolongation and its associated risks with antipsychotics. |
| Q38757870 | Cardiovascular safety of antipsychotics: a clinical overview |
| Q86661345 | Choice of baseline in parallel thorough QT studies |
| Q43059195 | Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. |
| Q34300628 | Drug safety and efficacy evaluation of sertindole for schizophrenia |
| Q51406750 | Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. |
| Q34259088 | Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study |
| Q51300430 | Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. |
| Q36514742 | Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program. |
| Q42427678 | Emerging role of sertindole in the management of schizophrenia |
| Q34129334 | Emerging treatments in the management of schizophrenia - focus on sertindole |
| Q55035299 | Evaluating cardiac risk: exposure response analysis in early clinical drug development. |
| Q50559385 | Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity. |
| Q35044184 | QT dynamics during treatment with sertindole |
| Q38244346 | QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review |
| Q43258117 | Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. |
| Q37809874 | Sertindole for the treatment of schizophrenia. |
| Q38236032 | Sertindole in schizophrenia: efficacy and safety issues. |
| Q48512500 | Sertindole: dilemmas for its use in clinical practice |
| Q86280920 | The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs |
| Q35731977 | The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. |
Search more.